Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    93
    ...
ATC Name B/G Ingredients Dosage Form Price
J01DH03 ERTAPENEM INJECTION G Ertapenem - 1g 1g Injectable concentrate for solution 26,153,163 L.L
J01CA01 AMPICILLINE PANPHARMA G Ampicillin (sodium) - 1g 1g Injectable powder for solution 2,857,009 L.L
A07EC02 ASACOL B Mesalazine - 1g/100ml 1g/100ml Enema 2,748,158 L.L
L01BC05 GEMCITABIN EBEWE G Gemcitabine (HCl) - 1g/100ml 1g/100ml Injectable concentrated solution 7,512,674 L.L
N02BE01 STOPALGIC G Paracetamol - 1g/100ml 1g/100ml Injectable solution 1,536,012 L.L
N02BE01 SOLUFLEX PARACETAMOL G Paracetamol - 1g/100ml 1g/100ml Injectable solution 211,175 L.L
N02BE01 ? PARACETAMOL G Paracetamol - 1g/100ml 1g/100ml Injectable solution 191,978 L.L
J06BA02 IG VENA BioHuman Human normal immunoglobulin - 1g/20ml 1g/20ml Injectable solution 7,474,948 L.L
J01DD04 MEGION-A G Ceftriaxone - 1g/3.5ml, Lidocaine (ampoule) - 1g/3.5ml Injectable powder + solvent 623,468 L.L
P02CB01 VERMIFUGE G Piperazine citrate - 1g/5ml 1g/5ml Syrup 148,463 L.L
L01BC05 GEMCI-CELL G Gemcitabine (HCl) - 1g/Vial 1g/Vial Injectable concentrate for solution 9,326,123 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 1mcg 1mcg Capsule 3,735,882 L.L
A11CC03 DERIL G Alfacalcidol - 1mcg 1mcg Capsule, soft 783,460 L.L
L01CX01 YONDELIS B Trabectedin - 1mg 1mg Injectable powder for solution 126,536,515 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 1mg 1mg Tablet 823,775 L.L
L01CX01 TRABECTEDIN EVER PHARMA G Trabectedin - 1mg 1mg Injectable powder for concentrate for solution 88,574,985 L.L
N05AX08 RESPAL 1 G Risperidone - 1mg 1mg Caplet, film coated 309,084 L.L
N05AX08 RISPERIDONE BIOGARAN G Risperidone - 1mg 1mg Tablet, coated, scored 643,701 L.L
M04AC01 COLCHICINE OPOCALCIUM B Colchicine - 1mg 1mg Tablet, scored 288,926 L.L
M04AC01 COLCHICINE BENTA G Colchicine - 1mg 1mg Tablet, film coated 332,761 L.L
L01XK04 TALZENNA B Talazoparib - 1mg 1mg Capsule 401,512,167 L.L
M04AC01 COLCHICINE SEID G Colchicine - 1mg 1mg Tablet 382,995 L.L
A06AX05 RESOLOR B Prucalopride succinate - 1mg 1mg Tablet, film coated 3,273,600 L.L
N05AX08 RISCHOTIC OD 1 G Risperidone - 1mg 1mg Tablet, orally disintegrating 371,157 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 1mg 1mg Tablet, film coated 2,015,764 L.L
A10BJ06 OZEMPIC B Semaglutide - 1mg 1mg Injectable solution 10,927,526 L.L
A10BJ06 SEMATIDE G Semaglutide - 1mg 1mg Injectable solution 9,288,397 L.L
C03CA02 BURINEX B Bumetanide - 1mg 1mg Tablet 335,961 L.L
A10BX02 NOVONORM B Repaglinide - 1mg 1mg Tablet 571,133 L.L
A10BX02 REPAGLINIDE ARROW LAB G Repaglinide - 1mg 1mg Tablet 831,839 L.L
    ...
    93
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025